Alain Mina

Serving at the NIH was by far one of the greatest honors of my career… @NIH @theNCI

@YaleCancer @YaleHematology Amazing!

New study led by Dr. Luca Lanino @YaleHematology analyzes the genomics of chronic myelomonocytic leukemia through a large international collaboration, identifying 9 molecular subtypes of #CMML and introducing #iCPSS, a genomics-based risk calculator to improve prognosis and guide treatment planning (icpss-risk.com) ascopubs.org/doi/10.1200/JC… @Dr_AmerZeidan @SmilowCancer @JCO_ASCO

@Dr_AmerZeidan @YaleCancer @YaleHematology @Yale @YaleMed @YaleMedicine Always wonderful partnering with you Amer. Let’s keep creating.

Our newest paper led by our own @dralainmina on the Pharmacologic progress in higher-risk MDS (or lack of): an uphill battle @YaleCancer @YaleHematology @Yale @YaleMed @YaleMedicine tandfonline.com/doi/full/10.10…

2️⃣ Permissive HLA-DPB1 Mismatch with PTCy Reduces Relapse in High-Risk AML/MDS Allo transplant donor selection in high-risk AML/MDS may be optimized by allowing permissive HLA-DPB1 mismatches when using PTCy. In a Leukemia study, permissive DPB1 mismatches were associated with lower relapse vs fully matched donors (2-year: 18% vs 28%; HR 0.6), with the greatest benefit in high-risk disease. nature.com/articles/s4137…

A great morning of presentations at our annual post-ASH meeting hosted by @NataliaNeparid1 Thoughtful questions & excellent talks highlighting new data and exciting #clinicaltrials for patients with hematologic malignancies. @YaleHematology @MaxStahlMD @Dr_AmerZeidan #ASH25.

The conundrum of drug development in higher-risk #MDSsm: lessons learned from recently failed phase 3 clinical trials ashpublications.org/blood/article-…

Dr. Stephanie Halene @Halene_lab was honored with the @YaleCancer Basic Science Research Award for her research identifying new and promising targets for future treatments in patients with acute megakaryoblastic leukemia. #AMKL ashpublications.org/blood/article-… @BloodPortfolio

Colleagues and friends discussing Evolving Treatment Strategies in Acute Myeloid Leukemia. onclive.com/peer-exchange/… Joshua Zeidner, Jessica Altman, Martha L. Arellano, Courtney DiNardo and Thomas W. LeBlanc

Congratulations to ⁦@MinaXu7⁩ of ⁦@yalepathology⁩ on delivering the Ronald Dorfman Lectureship at ⁦@StanfordPath⁩ this Monday, Jan 26! Friends in the South Bay interested in #spatialomics #spatial pathology—don’t miss it 🤩🤩🤩 med.stanford.edu/pathology/gran…

A Phase 1 study by Dr. Noffar Bar @YaleHematology shows subcutaneous alnuctamab #ALNUC is active in #RRMM, with a 58–71% response rate, ~50% of patients achieving MRD negativity, and better safety than IV dosing. #multiplemyeloma nature.com/articles/s4137… @SmilowCancer @LeukemiaJnl

Excited to see our review on #VEXAS now out in @TheLancet. A collaborative effort from our amazing @NIH @NIH_NIAMS NHLBI VEXAS team @bhavishap29 @petercgrayson Alice Fike, Kaitlin Quinn, Ben Turturice sciencedirect.com/science/articl…

In an @NEJM editorial, @DrRoyHerbstYale notes while new phase 3 options for EGFR-mutated #NSCLC show promise, added toxicity underscores the need for smarter combinations to extend survival & move closer to cure. nejm.org/doi/full/10.10… @SmilowCancer @YaleMed @YaleThoracic

Very proud of the immensely productive #ASH25 that our team at @YaleCancer @YaleHematology @Yale @YaleMed had showing the amazing work & science we do. Particularly proud of our fellows, trainees & junior faculty who delivered multiple oral presentations & presented many posters

@MinaXu7 Thank you Mina.Going through the uncertainty at the NIH last year, found myself thinking a lot about him. Perhaps he was reminding me of my “why”. Thanks for sharing :)

@dralainmina Such a thoughtful piece. I also rotated on palliative care as an elective in med school and have my own Daniel. It’s a wonderful testament to the kind of life that can be lived, even at the end of it.

Stepping outside the language of Science for a moment. A side of the work we don’t often publish. doi.org/10.1200/OP-25-…

@HindRafei Thank you dear friend ❤️

@dralainmina Powerful and moving piece! Beautifully written, and deeply respectful to patients and to what we go through. Thank you for sharing it 💕

Dr. Stephanie Halene @Halene_lab chairs an #ASH25 Scientific Symposia session exploring hematopoiesis in the golden years — from aging and epigenetic landscapes to clonal destiny. @YaleHematology @SmilowCancer

as #ASH25 starts, our team is pleased to share the publication of a tour-de-force review on the global epidemiology of #AMLsm published in @Nature Reviews of Clinical Oncology (You can read entire paper free online at rdcu.be/eTiuA @YaleCancer @Yale @YaleHematology

@Dr_AmerZeidan @Yale @TradIMYale @MarkDSiegel1 I love this!

Is there any residency program whose residents love and respect their program director more than @Yale @TradIMYale love and respect Dr @MarkDSiegel1 ?